glp 1 agonist in heart failure GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms It's important to study the

The considerable enzyme affinity implies a longer pharmacodynamic effect of this compound, with its short plasma half-lives that may not require dose adjustments in patients with renal dysfunction [32]

These guidelines recommend a comprehensive strategy be followed to reduce risks of CKD in people living with T2DM and are summarized in Fig

Consult with your physician to confirm you meet the criteria for GLP-1 therapy

Data on patient-reported outcomes for individual GLP-1RAs indicate high treatment satisfaction rates with the long-acting agents (Table 3) [69,70,71,72,73,74], while dulaglutide was associated with higher adherence and persistence rates than exenatide QW and liraglutide [75]